A prospective, double‐blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention
Bin Nie(Capital Medical University), Yujie Zhou(Shanghai Jiao Tong University), Yanfang Li(Chinese Academy of Sciences), Zheng Cao(Chinese Academy of Sciences), Wan-jun Cheng(Capital Medical University), Qing Yang(Guangzhou University of Chinese Medicine), Yong‐He Guo(Capital Medical University), Yingxin Zhao(The University of Texas Medical Branch at Galveston)
Cited by 62
Related Papers
Sumoylation Promotes the Stability of the DNA Sensor cGAS and the Adaptor STING to Regulate the Kinetics of Response to DNA Virus
|Immunity|2016|378
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma
|Clinical Cancer Research|2018|218
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
|British Journal of Cancer|2018|156
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer
|Science Translational Medicine|2019|138